Location History:
- Newark, CA (US) (2021 - 2022)
- Hayward, CA (US) (2014 - 2023)
- Thousand Oaks, CA (US) (2024)
Company Filing History:
6 out of 9 
3 out of 3 
3 out of 3 Years Active: 2014-2025
Sure, here is the article about inventor Shelley Force Aldred:
Title: Innovator Spotlight: Shelley Force Aldred - Pioneering Antibody Therapeutics in B-cell Disorders
Introduction:
Shelley Force Aldred, a prolific inventor based in Hayward, CA, has left an indelible mark in the field of biotechnology with his groundbreaking work in developing novel antibody therapeutics for B-cell disorders. With a keen focus on innovation and scientific excellence, Aldred has amassed an impressive portfolio of 13 patents, showcasing his dedication to advancing healthcare through cutting-edge research.
Latest Patents:
Aldred's recent patents include the groundbreaking "Anti-BCMA heavy chain-only antibodies" and "Heavy chain antibodies binding to CD22." These innovative technologies, such as UniAb and UniAbs™, not only demonstrate his expertise in antibody engineering but also offer promising treatment avenues for B-cell disorders characterized by the expression of BCMA and CD22.
Career Highlights:
Throughout his career, Aldred has made significant contributions to the biopharmaceutical industry, particularly during his tenure at Teneobio, Inc. and Teneoone, Inc. His work reflects a deep commitment to translating scientific discoveries into tangible therapeutic solutions, with a focus on addressing unmet medical needs in the field of immunology.
Collaborations:
Aldred has had the privilege of collaborating with esteemed colleagues such as Nathan D Trinklein and Katherine Harris, who have contributed to the success of his research endeavors. Their collective efforts have led to the development of novel antibody-based therapies that hold great promise for patients suffering from B-cell disorders.
Conclusion:
In conclusion, Shelley Force Aldred stands as a trailblazer in the field of antibody therapeutics, with a remarkable track record of innovation and scientific achievement. His pioneering work in developing novel treatment modalities for B-cell disorders underscores his dedication to advancing healthcare and improving patient outcomes. As he continues to push the boundaries of scientific discovery, Aldred's impact on the biopharmaceutical landscape is sure to endure for years to come.
If you have any further questions or need additional information, feel free to reach out.